OT mobile menu

Search form


ASCO 2015 Breast Cancer Symposium

ASCO 2015 Breast Cancer Symposium

Stay connected with the OncoTherapy Network as we highlight some of presentations taking place at the ASCO 2015 Breast Cancer Symposium, September 25-27 in San Francisco.

ASCO 2015 Breast Cancer Symposium

This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.

Caveolin-1 (CAV1) appears to play an oncogenic role in breast cancer by fostering molecular hubs for signaling, and should be considered a potential target for therapeutic investigation, in particular in triple-negative disease.

Multigene panels can detect significant pathogenic mutations in a proportion of breast cancer patients who have tested negative for BRCA1/2 gene mutations, according to a new study.

High expression of the known tumor promotor TOX3 gene leads to poorer prognosis in breast cancer patients with luminal B disease, according to a new study.

Neratinib significantly improves invasive disease-free survival (iDFS) in trastuzumab (Herceptin)-treated, early-stage, human epidermal growth factor receptor 2-positive (HER2+) breast cancer patients, with an enhanced treatment effect observed in women with centrally confirmed HER2+ tumors.

More accurate identification of molecular subtyping for breast cancer may be able to identify patients with chemosensitivity to specific therapies, according to a new study.

Aromatase inhibitors can reduce risk of contralateral breast cancer in women who have a BRCA mutation, according to a new study.


Subscribe to ASCO 2015 Breast Cancer Symposium on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.